Clustering and co-evolution to construct neural network ensembles: an experimental study.

Neural Netw

School of Computer Science, The University of Birmingham, Edgbaston, Birmingham, B15 2TT, UK.

Published: November 2008

This paper introduces an approach called Clustering and Co-evolution to Construct Neural Network Ensembles (CONE). This approach creates neural network ensembles in an innovative way, by explicitly partitioning the input space through a clustering method. The clustering method allows a reduction in the number of nodes of the neural networks that compose the ensemble, thus reducing the execution time of the learning process. This is an important characteristic especially when evolutionary algorithms are used. The clustering method also ensures that different neural networks specialize in different regions of the input space, working in a divide-and-conquer way, to maintain and improve the accuracy. Besides, the clustering method facilitates the understanding of the system and makes a straightforward distributed implementation possible. The experiments performed with seven classification databases and three different co-evolutionary algorithms show that CONE considerably reduces the execution time without prejudicing (and even improving) the accuracy, even when a distributed implementation is not used.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neunet.2008.02.001DOI Listing

Publication Analysis

Top Keywords

clustering method
16
neural network
12
network ensembles
12
clustering co-evolution
8
co-evolution construct
8
construct neural
8
input space
8
neural networks
8
execution time
8
distributed implementation
8

Similar Publications

Drug Development.

Alzheimers Dement

December 2024

Aptah Bio Inc., San Carlos, CA, USA.

Background: Alzheimer's disease (AD) is the most common cause of dementia worldwide. It is characterized by dysfunction in the U1 small nuclear ribonucleoproteins (snRNPs) complex, which may precede TAU aggregation, enhancing premature polyadenylation, spliceosome dysfunction, and causing cell cycle reentry and death. Thus, we evaluated the effects of a synthetic single-stranded cDNA, called APT20TTMG, in induced pluripotent stem cells (iPSC) derived neurons from healthy and AD donors and in the Senescence Accelerated Mouse-Prone 8 (SAMP8) model.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Vigil Neuroscience, Inc, Watertown, MA, USA.

Background: TREM2 is a lipid-sensing receptor expressed by microglial sub-populations within neuropathological microenvironments, whose downstream signaling promotes microglial survival, plasticity, and migration. Multiple loss-of-function variants strongly implicate TREM2 as a key regulator of Alzheimer's disease (AD) risk. Accordingly, TREM2 antibodies are currently in development to evaluate the therapeutic potential of TREM2 agonism in neurodegenerative diseases.

View Article and Find Full Text PDF

Background: Focusing on novel AD treatments, the TREAT-AD centers offer an array of free research tools, shared via the AD Knowledge Portal in a Target Enablement Package (TEP). This abstract showcases the research conducted by the IUSM-Purdue TREAT-AD Center, specifically focusing on Targeting class-II PI3K's as a potential breakthrough in AD therapy. Endocytosis within the brain encompasses diverse pathways for internalizing extracellular cargoes and receptors into cells.

View Article and Find Full Text PDF

Drug Development.

Alzheimers Dement

December 2024

Vigil Neuroscience, Inc, Watertown, MA, USA.

Background: TREM2 is a lipid-sensing receptor expressed by microglial sub-populations within neuropathological microenvironments, whose downstream signaling promotes microglial survival, plasticity, and migration. Multiple loss-of-function variants strongly implicate TREM2 as a key regulator of Alzheimer's disease (AD) risk. Accordingly, TREM2 antibodies are currently in development to evaluate the therapeutic potential of TREM2 agonism in neurodegenerative diseases.

View Article and Find Full Text PDF

Background: Understanding the fundamental differences between the human and pre-human brain is a prerequisite for designing meaningful models and therapies for AD. Expressed CHRFAM7A, a human restricted gene with carrier frequency of 75% in the human population predicts profound translational significance.

Method: The physiological role of CHRFAM7A in human brain is explored using multiomics approach on 600 post mortem human brain tissue samples (ROSMAP).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!